1887

Chapter 8 : Patterns in the Emergence of Epidemic Meningococcal Disease

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Patterns in the Emergence of Epidemic Meningococcal Disease, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816940/9781555811211_Chap08-1.gif /docserver/preview/fulltext/10.1128/9781555816940/9781555811211_Chap08-2.gif

Abstract:

This chapter reviews several recent surges in disease activity caused by the three main meningococcal serogroups (A, C and B) in the 1990s and discusses current and future strategies for prevention. The mortality rate of untreated meningococcal meningitis has not been recorded recently but was reported to be as high as 75% in the preantibiotic era. The precise reason for the distinct seasonality is unclear but may be related to the drying effect on mucous membranes, seasonal transmission of respiratory viruses, or other factors. More importantly, drying of the nasopharyngeal mucosa or intercurrent respiratory tract infections may contribute to invasiveness, transmission of carriage, or both. Complete immunization coverage with the polysaccharide vaccine is critical to halt epidemic disease. In the early 1990s, public health personnel in Oregon noticed increasing rates of meningococcal disease in the general population but surprisingly not in focal outbreaks. The epidemiologic pattern of disease was similar to endemic patterns in most respects, including seasonality, sex distribution, and mortality rates. A constant low level of disease is caused by a variety of serogroups and, within each serogroup, a variety of individual strains. The recent history of meningococcal disease outbreaks due to serogroups A, B, and C suggests that epidemic strains will continue to arise and cause major public health crises in both developing and developed countries.

Citation: Wenger J, Perkins B. 1998. Patterns in the Emergence of Epidemic Meningococcal Disease, p 125-136. In Scheld W, Armstrong D, Hughes J (ed), Emerging Infections 1. ASM Press, Washington, DC. doi: 10.1128/9781555816940.ch8

Key Concept Ranking

Outer Membrane Proteins
0.5010494
Meningococcal Disease
0.42914298
0.5010494
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1.
Figure 1.

The sub-Saharan African meningitis belt.

Citation: Wenger J, Perkins B. 1998. Patterns in the Emergence of Epidemic Meningococcal Disease, p 125-136. In Scheld W, Armstrong D, Hughes J (ed), Emerging Infections 1. ASM Press, Washington, DC. doi: 10.1128/9781555816940.ch8
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2.
Figure 2.

Epidemiology of meningitis in Niger, a country located in the African meningitis belt from 1919 through 1989. (Reprinted from reference with permission.)

Citation: Wenger J, Perkins B. 1998. Patterns in the Emergence of Epidemic Meningococcal Disease, p 125-136. In Scheld W, Armstrong D, Hughes J (ed), Emerging Infections 1. ASM Press, Washington, DC. doi: 10.1128/9781555816940.ch8
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3.
Figure 3.

Epidemic curve from a group A meningococcal disease epidemic in Nairobi, Kenya, in 1989, The solid line shows the actual number of cases which occurred by week, including those that occurred after mass immunization campaigns. The dashed line shows modelled data with the estimated number of cases which would have occurred without any vaccination program. The space between these two lines represents the number of cases actually prevented, However, the dotted line shows modelled data of the number of cases which would have been prevented if immunization had been carried out according to the time line set forth in the Current World Health Organization guidelines, and it shows that a much larger number of cases were preventable by mass vaccination ( ).

Citation: Wenger J, Perkins B. 1998. Patterns in the Emergence of Epidemic Meningococcal Disease, p 125-136. In Scheld W, Armstrong D, Hughes J (ed), Emerging Infections 1. ASM Press, Washington, DC. doi: 10.1128/9781555816940.ch8
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 4.
Figure 4.

Incidence of reported meningococcal disease in the United Stales by year from 1920 through 1995.

Citation: Wenger J, Perkins B. 1998. Patterns in the Emergence of Epidemic Meningococcal Disease, p 125-136. In Scheld W, Armstrong D, Hughes J (ed), Emerging Infections 1. ASM Press, Washington, DC. doi: 10.1128/9781555816940.ch8
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 5.
Figure 5.

Multilocus enzyme electrophoresis dendrogram of serogroup B meningococci showing the location of the ET-5 complex. (From reference .)

Citation: Wenger J, Perkins B. 1998. Patterns in the Emergence of Epidemic Meningococcal Disease, p 125-136. In Scheld W, Armstrong D, Hughes J (ed), Emerging Infections 1. ASM Press, Washington, DC. doi: 10.1128/9781555816940.ch8
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555816940.chap8
1. Apicella, M. A., 1995. Neisseria meningitidis. p. 18961909. In G. L. Mandell,. R. G. Douglas,. and J. E. Bennett (ed.), Principles and Practice of Infecliolls Diseases. 4th ed. vol. 2. Churchill Livingstone Inc., New York. N.Y..
2. Ashton, F. E.,, J. A. Ryan,, A. Borczyk,, D. A. Caugant,, L. Mancino,, and D. Huang. 1991. Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada. J. Clin. Microbial. 29:24892493.
3. BaralT, L. J.,, S. I. Lee,, and D. L. Schriger. 1993. Outcomes of bacterial meningitis in children: a meta•ana1ysis. Pediatr. Infect. Dis. J. 12:389394.
4. Bjune, G.,, E. A. Hoiby,, J. K. Gronnesby,, O. Arnesen,, J. H. Fredriksen,, A. Halstensen,, E. Holten,, A. K. Lindbak,, H. Nokleby,, E. Rosenqvist,, L. K. Solberg,, O. Closs,, J. Eng,, L. O. Froholm,, A. Lystad,, L. S. Bakketeig,, and B. Hareide. 1991. Effect of an outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338:10931096.
5. Boslego, J.,, J. Garcia,, C. Cruz,, W. Zollinger,, B. Brandt,, S. Ruiz,, M. Martinez,, J. Arthur,, P. Underwood,, W. Silva, and the Chilean National Committee ror Meningococcal Disease. 1995. Efficacy, safety, and immunogenicity of a meningococcal vaccine group B (l5:P1.3) outer membrane protein vaccine in Iquique. Chile. Vaccine 13:821829.
6. Broome, C. V. 1986. The carrier state: Neisseria meningitidis. J. Antimicrob. ellemother. 18(Suppl. A):2534.
7. Caugant, D. A.,, L. O. Frohoim,, K. Bovre,, E. Holten,, C. E. Frasch,, L. F. Mocca,, W. D. Zollinger,, and R. K. Selander. 1986. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl. Acad. Sci. USA 83:49274931.
8.Centers for Disease Control. 1991. Haemophilus b conjugate vaccines for prevention of Haemophilus influenzae type b (Hib) disease among infants and children two months of age and older: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 40:16.
9..Centers for Disease Control and Prevention. 1995. Serogroup B meningococcal disease-Oregon, 1994. Morbid. Mortal. Weekly Rep. 44:121124.
10.Centers for Disease Control and Prevention. 1997. Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: evaluation and management of suspected outbreaks: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 46:121.
10.a. Centers for Disease Control and Prevention. Unpublished data.
11. DeWals, P.,, M. Dionne,, M. Douville-Fradet,, N. Bouilanne,, J. Drapeau,, and G. OeSerres. 1996. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec. Canada. Bull. W. H. O. 74:407411.
12. Fairley, C. K.,, N. Begg,, R. Borrow,, A. J. Fox,, D. M. Jones,, and K. Cartwright. 1996. Conjugate meningococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. Infect. Dis. 174:13601363.
13. Fischer, M.,, K. Hedberg,, P. Cardosi,, B. D. PJikaytis,, F. C. Hoesiy,, K. R. Steingart,, T. A. Bell,, D. W. Fleming,, J. D. Wenger,, and B. A. Perkins. Epidemic meningococcal disease and tobacco smoke: a risk factor study in the Pacific Northwest. Pediatr. Infect. Dis. J., in press.
14. Fischer, M.,, and B. A. Perkins. 1997. Neisseria meningitidis serogroup B: emergence of the ET•5 complex. Semin. Pediatr. Infect. Dis. 8:5056.
15. Flexner, S. 1913. The results of the serum treatment in thirteen hundred cases of epidemic meningitis. J. Exp. Med. 17:553576.
16. Frasch, C. E. 1989. Vaccines for prevemion of meningococcal disease. elin. Microbiol. Rev. 2(Suppl.):S134S138.
17. Gold, R.,, M. L. Lepow,, I. Goldscbneider,, T. F. Draper,and E. C. GotscbJicb. 1979. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children. J. Infect. Dis. 140:690697.
18. Goldscbneider, I.,, E. C. Gotschlich,, and M. S. Artenstein. 1969. Human immunity to the menin• gococcus. I. The role of humoral antibodies. J. Exp. Med. 129:13071326.
19. Gotscblicb, E. c.,, I. Goldscbneider,, and M. S. Artenstein. 1969. Human immunity to the menin• gococcus. IV. Immunogenicity of the group A and group C polysaccharides in human volunteers. J. Exp. Med. 129:13671384.
20. Greenwood, B. M., 1987. Epidemiology of meningitis in tropical Africa. p. 6191. In J. D. Williams, and J. Burnie (ed.). Bacterial meningitis, 1st ed. Academic Press, Inc., London, United Kingdom.
21. Greenwood, B. M.,, I. S. Blakebrough,, A. K. Bradley,, S. Wali,, and H. C. Wbittle. 1984. Meningococcal disease and season in sub-Saharan Africa. Lancet i:13391342.
22. Griffiss, J. M.,, B. L. Brandt,, and G. A. Jarvis,. 1987. Natural immunity to Neisseria meningitidis. p. 99119. In N. A. Vedros (ed.). Evolution of Meningococcal Disease. vol. II. CRC Press, Boca Raton. Fla..
23. Hume, S. E. 1992. Mass voluntary immunization campaigns for meningococcal disease in Canada: media hysteria. JAMA 267:18331838.
24. Jackson, L. A.,, A. Schuchat,, M. W. Reeves,, and J. D. Wenger. 1995. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 273:383389.
25. Jackson, L. A.,, and J. D. Wenger. 1993. Laboratory-based surveillance for meningococcal disease in selected areas, United States. 1989-1991. Morbid. Mortal. Weekly Rep. 42:2130.
26. Kaybty, H.,, V. Karanko,, H. Peltola,, S. Sarna,, and P. H. Makela. 1980. Serum antibodies to capsular polysaccharide vaccine of group A Neisseria meningitidis followed for three years in infants and children. J. Infect. Dis. 142:861868.
27. Leach, A.,, P. A. Twumasi,, S. Kumah,, W. S. Banya,, S. JalTar,, B. D. Forrest,, D. M. GranolT,, D. E. LiButti,, G. M. Carlone,, L. B. Pais,, C. V. Broome,, and B. M. Greenwood. 1997. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J. Infect. Dis. 175:200204.
28. Lennon, D.,, B. Gellin,, D. Hood,, L. Voss,, H. HelTeman,, and S. Thakur. 1992. Successful inter• vention in a group A meningococcal outbreak in Auckland. New Zealand. Pediatr. Infect. Dis. J. 11:617623.
29. Lennon, D.,, L. Voss,, J. Sinclair,, and H. Heffernan. 1989. An outbreak of meningococcal disease in Auckland. New Zealand. Pediatr. Infect. Dis. J. 8:1115.
30. Lieberman, J. M.,, S. S. Chiu,, V. K. Wong,, S. Partridge,, S. J. Chang,, C. Y. Chiu,, L. L. Gbeesling,, G. M. Carlone,, and J. I. Ward. 1996. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharide-protein conjugate vaccine in young children. JAMA 275:14991503.
31. Moore, P. S.,, J. Hierbolzer,, W. DeWitt,, K. Gouan,, D. Djore,, T. Lippeyeld,, B. Plikaytis,, and C. V. Broome. 1990. Respiratory viruses and mycoplasma as cofactors for epidemic group A meningococcal meningitis. JAMA 264:12711275.
32. Moore, P. S.,, B. D. Plikaytis,, G. A. Bolan,, M. J. Oxtoby,, A. Yada,, A. Zoubga,, A. L. Reingold,, and C. V. Broome. 1992. Detection of meningitis epidemics in Africa: a population-based analysis. Int. J. Epidemiol. 21:155162.
33. Moore, P. S.,, M. W. Reeyes,, B. Scbwartz,, B. G. Gellin,, and C. V. Broome. 1989. Intercontinental spread of an epidemic group A Neisseria meningitidis strain. Lancet ii:260263.
34. Moraes, J. C.,, B. A. Perkins,, M. C. C. Camargo,, N. T. R. Hidalgo,, H. A. Barbosa,, C. T. Sacchi,, I. M. L. Gral,, V. L. Gattas,, H. G. Vasconcelos,, B. D. Plikaytis,, J. D. Wenger,, and C. V. Broome. 1992. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 340:10741078.
35. Olyhoek, T.,, B. A. Crowe,, and M. Achtman. 1987. Clonal population structure of Neisseria meningitidis serogroup A isolated from epidemics and pandemics between 19 15 and 1983. Rev. Infect. Dis. 9:665692.
36. Peltola, H. 1983. Meningococcal disease: still with us. Rev. Injecl. Dis. 5:7191.
37. Peitola, H.,, J. M. Kataja,, and P. H. Makela. 1982. Shift in age distribution of meningococcal disease as predictor of an epidemic? Lancet ii:595597.
38. Peltola, H.,, P. H. Makela,, H. Kiiyhty,, H. Jousimies,, E. Herva,, K. Hallstrom,, A. Sivonen,, O. V. Renkonen,, O. Pettay,, V. Karanko,, P. Ahvonen,, and S. Sarna. 1977. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N. Engl. J. Med. 297:686691.
39. Pinner, R. W.,, F. Onyango,, B. A. Perkins,, N. Mirza,, D. M. Ngacha,, M. Reeves,, W. DeWitt,, E. Njeru,, N. N. Agata,, and C. V. Broome. 1992. Epidemic meningococcal disease in Nairobi, Kenya-1989. J. Inject. Dis. 166:359364.
40. Reeves, M. W.,, B. A. Perkins,, M. Diermeyer,, and J. D. Wenger. 1995. Epidemic-associated Neisseria meningitidis detected by multilocus enzyme electrophoresis. Emerg. Infect. Dis. 1:5354.
41. Reingold, A. L.,, C. V. Broome,, A. W. Hightower,, G. W. Ajello,, G. A. Bolan,, C. Adamsbaum,, E. E. Jones,, C. Phillips,, H. Tiendrebeogo,, and A. Yado. 1985. Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet ii:114118.
42. Riedo, F. X.,, B. D. Plikaytis,, and C. V. Broome. 1995. Epidemiology and prevention of meningococcal disease. Pediatr. Inject. Dis. J. 14:643657.
43. Rosenstein, N.,, O. Levine,, J. Taylor,, M. Weldon,, B. Ray,, B. Plikaytis,, J. D. Wenger,, and B. A. Perkins. 1996. Persistent serogroup C meningococcal disease outbreak in a vaccinated population. Gregg County, Texas, abstr. 0-84. p. 158. In Abstracts of the 36th Interscience Conference on Anlimkrohial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C..
44. Saeehi, C. T.,, L. L. Pessoa,, S. R. Ramos,, L. G. Milagres,, M. C. C. Camargo,, N. T. R. Hidalgo,, C. E. A. Melles,, D. A. Caugant,, and C. E. Frasch. 1992. Ongoing group B Neisseria meningitidis epidemic in Sao Paulo, Brazil, due to increased preva lence of a single clone of the ET-5 complex. J. Clin. Microbial. 30:17341738.
45. Sierra, G. V. G.,, H. C. Campa,, N. M. Vareaeel,, I. L. Garcia,, P. L. Izquierdo,, P. F. Sotolongo,, G. V. Casanueva,, C. O. Rico,, C. R. Rodriguez,, and M. H. Terry. 1991. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination resul ts in Cuba. NIPH Ann. 14:195207.
46. Twumasi, P. A., Jr.,, S. Kumah,, A. Leach,, T. J. O' Dempsey,, S. J. Ceesay,, J. Todd,, C. V. Broome,, G. M. Carlone,, L. B. Pais,, and P. K. Holder. 1995. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J. Infect. Dis. 171:632638.
47. Vieusseaux, M. 1805. Memoire sur la maladie qui a regne a Geneve au printemps de 1805. J. Med. Chir. Pharm. 11:163182.
48. Whalen, C. M.,, J . C. Hockin,, A. Ryan,, and F. Ashton. 1995. The changing epidemiology of invasive meningococcal disease in Canada, 1985 through 1995. Emergence of a virulent clone of Neisseria meningitidis. JAMA 273:390394.
49.World Health Organization. 1995. Meningococcal disease-Mongolia. Weekly Epidemiol. Rep. 40:281282.
50.World Health Organization. 1996. Cerebrospinal meningitis in Africa. Weekly Epidemiol. Rep. 42:318319.
51.World Health Organization Working Group. 1995. Control of epidemic meningococcal disease. WHO practical guidelines, 1st ed. Foundation Marcel Merieux, Lyon. France.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error